Core Viewpoint - Hutchison China MediTech Limited (和黄医药) will present updated research findings on its self-developed compounds at two major conferences in 2025, highlighting its ongoing commitment to advancing cancer treatment [1] Group 1: Upcoming Conferences - The 2025 World Lung Cancer Conference (WCLC) will take place in Barcelona, Spain from September 6 to 9, 2025 [1] - The 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) will be held in Jinan, China from September 10 to 14, 2025 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and an Ib phase validation study on Savolitinib for treating non-small cell lung cancer will be presented at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]
和黄医药(00013.HK)将于2025年世界肺癌大会和中国临床肿瘤学会2025年年会公布数据